Posted by MARKED on March 20, 2004, at 14:57:17
In reply to Re: Selegiline Patch FDA Update - Tom, Spike, posted by Elizabeth on January 14, 2002, at 19:15:16
Quite true, with all the pharmaceutical companies competition and the high cost of FDA approval, ROCHE has declined to initiate the process in North America. It is available in Canada, Europe, Australia and the Net. I was on it for up to 2 years (and on/off for 4 years). It is definately recommended by me, and I believe with a SSRI or the original (taken off shelves with no reason -Brofaromine (which was this very type of combination)it would have been a good combination). Funny enough, the pharmeceutical companies are working on many of these types of dual combined medications to this day, it's all money & politics. They are using old drugs and renaming most of them with slight differences in their chemical structures with other well known antidepressant medications, to create a combined acting drug with minimal side-effects.
----MARKED
> Spike:
> > I thought RIMA MAOIs were not marketed in the US because of lack of efficacy .... studies for depression were not that conclusive so the drug companies abandoned approval? Is that wrong?
>
> The rumor I heard was that, in the case of moclobemide at least, Roche decided not to bother marketing it in the U.S. because the market was already flooded with SSRIs and such. I'm inclined to believe it because I seem to recall other situations in which Roche has been kind of chicken about new drugs (especially in the U.S., where it's particularly hard to get them approved), if you ask me -- it's like they had Librium and Valium, and now they're resting on their laurels.
>
> -elizabeth
poster:MARKED
thread:89603
URL: http://www.dr-bob.org/babble/20040319/msgs/326452.html